Personalized computer-guided planning for radioembolization in liver cancer
Official title: An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies for Liver Cancer
Run by University Hospital, Ghent · NCT07315633 · Data updated 2026-11-12
This project will try using patient-specific computer models of liver blood flow to predict where radioactive microspheres go during transarterial radioembolization for people with hepatocellular carcinoma.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | University Hospital, Ghent Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Ghent) |
| Status | Recruiting |
| Started | September 23, 2025 |
| Main results expected | September 22, 2029 |
| Study ends | December 31, 2030 |
| Registry record updated | January 2, 2026 |
| Trial ID | NCT07315633 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with radiologically confirmed hepatocellular carcinoma who are eligible for or planned to receive TARE and who have suitable pre-treatment hepatic vascular imaging are ideal candidates.
✕Probably not a fit
Patients without adequate pre- or post-treatment hepatic imaging, those not undergoing TARE, or those with non-HCC liver lesions are unlikely to benefit from this platform.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study builds patient-specific 3D models of the hepatic arterial tree from clinical imaging (CT, MRI, PET, SPECT, or DSA) and uses computational fluid dynamics (CFD) to simulate blood flow and microsphere transport. Simulations will account for procedural variables such as catheter tip location, orientation, and injection velocity to predict microsphere distribution and radiation dose deposition. Simulated dosimetry will be compared with available pre- and post-treatment imaging and clinical data to identify anatomical and procedural factors that influence outcomes. The long-term aim is to create a pre-treatment planning platform to make TARE delivery more predictable and personalized.
Why it matters
Potential benefit: If successful, the platform could make TARE more predictable and effective by improving tumor dose delivery while reducing radiation to healthy liver.
How similar studies have gone: Prior computational and pilot studies have suggested CFD can help predict microsphere behavior, but fully validated patient-specific CFD pre-planning for TARE remains largely experimental.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects radiologically diagnosed with HCC, eligible for or undergoing treatment. * Subjects who are treated (or will be treated) using TARE with radioactive microspheres. * Subjects for whom pre-treatment medical imaging of the hepatic arterial vasculature was performed for TARE planning (e.g., CT, MRI, PET, SPECT, and DSA), which can be used to develop patient-specific 3D models of the hepatic arterial tree and treatment dose distribution. Exclusion Criteria: * Subjects undergoing TARE procedures without adequate medical imaging of the hepatic vasculature. * Subjects in whom no pre- or post-treatment imaging data are available for analysis.
Where it's running
-
University Hospital Ghent
Ghent, Belgium Recruiting
Study contacts
- Study coordinator: Elisabeth Dhondt, Dr.
- Email: Elisabeth.dhondt@uzgent.be
- Phone: +32 9 3326684
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MTS105 treatment for advanced liver cancer
This study is testing a new treatment called MTS105 for people with advanced liver cancer to see if it can help their immune system fight the cancer after other treatments haven't worked.
-
Evaluating liver cancer treatments and their impact on quality of life
This study is testing how two different liver cancer treatments affect the quality of life for patients with hepatocellular carcinoma.
-
ET140203 T Cells for treating pediatric liver cancer
This study is testing a new type of T-cell treatment for kids with certain types of liver cancer to see if it is safe and helps them feel better.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer
This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.
-
AI-guided treatment choices for advanced liver cancer
Researchers are testing an AI tool to help predict which patients with advanced hepatocellular carcinoma will respond to modern systemic therapies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.